ArticleAIDS research and therapy2025
Clinical application of the urinary lipoarabinomannan (AIMLAM) test in PLHIV with TB.
Article in AIDS research and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Efficacy of a chemiluminescence-based urinary LAM (AIMLAM) assay in the diagnosis of active TB in Chinese children.Microbiology spectrum · 2026Article
- Towards tuberculosis elimination in people with HIV on antiretroviral therapy: evidence from a two-decade nationwide cohort in Spain.Infectious diseases of poverty · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveTo evaluate the diagnostic performance and clinical utility of a new antigen test for the detection of urinary lipoarabinomannan (AIMLAM) in people living with HIV (PLHIV) with comorbid tuberculosis (TB).
methodsThis study included 82 PLHIV who were presumed to have TB and were admitted to Yunnan Infectious Disease Hospital from December 1, 2023, to July 1, 2024. General clinical data were collected. Urine samples were collected from all patients and subjected to AIMLAM antigen detection via chemiluminescence. Appropriate samples (such as sputum or other samples) were collected from patients in good condition for MGIT 960 mycobacterial culture (MGIT 960), GeneXpert-MTB/RIF testing (Xpert), and acid‒fast bacillus staining (AFB). According to the gold standard for outcome prediction, the patient’s history, clinical symptoms, confirmed microbiological features, and radiological/imaging findings, etc., were integrated to predict the overall outcome.
resultsUrinary AIMLAM antigen detection demonstrated greater sensitivity (83.3%) and specificity (70.7%) than MGIT 960 culture, GeneXpert-MTB/RIF, and AFB staining for diagnosing advanced HIV disease (AHD)-related TB. The diagnostic efficacy of urinary AIMLAM antigen detection was superior to that of the other tests, with an area under the curve (AUC) of 0.774, indicating significant clinical value in diagnosing TB among patients with AHD. There were 33 AIMLAM antigen-positive cases with CD4 cell counts ≤ 200 cells/µL, but the results for 14 cases were identified as false positives because of coinfections with nontuberculous mycobacteria (NTM), invasive fungal infections, or severe bacterial infections. Statistically significant differences in signal-to-cutoff ratio (S/CO) values from AIMLAM testing were observed among patients with mycobacterial, fungal, and bacterial infections (P < 0.05), but no significant difference was detected between patients with TB and those with NTM infections (P > 0.05).
conclusionUrine AIMLAM antigen detection is an effective tool for initial screening of TB in patients with AHD. It has higher sensitivity than MGIT 960, GeneXpert-MTB/RIF, and AFB smear, but the method needs to be optimized to increase its specificity. Positive AIMLAM results with high S/CO values suggest mycobacterial infection, although it cannot be used to differentiate TB from NTM infections. Low S/CO values in HIV patients warrant the consideration of fungal or other opportunistic infections. Species-specific confirmation is needed before treatment initiation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.